Case study reviewNOBLE, Paul W; TANOUE, Lynn; HOMER, Robert et al.Chest. 2005, Vol 128, Num 5, pp 540S-546S, issn 0012-3692, SUP1Article

All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the Design and Execution of Clinical TrialsKING, Talmadge E; ALBERA, Carlo; BRADFORD, Williamson Z et al.American journal of respiratory and critical care medicine. 2014, Vol 189, Num 7, pp 825-831, issn 1073-449X, 7 p.Article

Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophagesHORTON, Maureen R; OLMAN, Mitchell A; BAO, Clare et al.American journal of physiology. Lung cellular and molecular physiology. 2000, Vol 23, Num 4, pp L707-L715, issn 1040-0605Article

Idiopathic pulmonary fibrosis and pulmonary hypertension : Connecting the dotsNATHAN, Steven D; NOBLE, Paul W; TUDER, Rubin M et al.American journal of respiratory and critical care medicine. 2007, Vol 175, Num 9, pp 875-880, issn 1073-449X, 6 p.Article

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisKING, Talmadge E; BRADFORD, Williamson Z; LEDERER, David J et al.The New England journal of medicine. 2014, Vol 370, Num 22, pp 2083-2092, issn 0028-4793, 10 p.Article

Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β₂-adrenoceptors and exacerbates lung inflammation in miceRUI LIN; DEGAN, Simone; BRODY, Arnold R et al.British journal of pharmacology. 2012, Vol 165, Num 7, pp 2365-2377, issn 0007-1188, 13 p.Article

Serum Inter-α-Trypsin Inhibitor and Matrix Hyaluronan Promote Angiogenesis in Fibrotic Lung InjuryGARANTZIOTIS, Stavros; ZUDAIRE, Enrique; NOBLE, Paul W et al.American journal of respiratory and critical care medicine. 2008, Vol 178, Num 9, pp 939-947, issn 1073-449X, 9 p.Article

6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisDU BOIS, Roland M; ALBERA, Carlo; BRADFORD, Williamson Z et al.The European respiratory journal. 2014, Vol 43, Num 5, pp 1421-1429, issn 0903-1936, 9 p.Article

Airway Fibroblasts in Asthma Manifest an Invasive PhenotypeINGRAM, Jennifer L; HUGGINS, Molly J; SUNDAY, Mary E et al.American journal of respiratory and critical care medicine. 2011, Vol 183, Num 12, pp 1625-1632, issn 1073-449X, 8 p.Article

Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary FibrosisDU BOIS, Roland M; WEYCKER, Derek; SZWARCBERG, Javier et al.American journal of respiratory and critical care medicine. 2011, Vol 184, Num 4, pp 459-466, issn 1073-449X, 8 p.Article

Patient experiences with pulmonary fibrosisCOLLARD, Harold R; TINO, Gregory; NOBLE, Paul W et al.Respiratory medicine. 2007, Vol 101, Num 6, pp 1350-1354, issn 0954-6111, 5 p.Article

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisRICHELDI, Luca; DU BOIS, Roland M; DONG SOON KIM et al.The New England journal of medicine. 2014, Vol 370, Num 22, pp 2071-2082, issn 0028-4793, 12 p.Article

Surfactant Protein-D Regulates Effector Cell Function and Fibrotic Lung Remodeling in Response to Bleomycin InjuryAONO, Yoshinori; LEDFORD, Julie G; MUKHERJEE, Sambuddho et al.American journal of respiratory and critical care medicine. 2012, Vol 185, Num 5, pp 525-536, issn 1073-449X, 12 p.Article

Role of hyaluronan and hyaluronan-binding proteins in human asthmaJIURONG LIANG; DIANHUA JIANG; JUNG, Yoosun et al.Journal of allergy and clinical immunology. 2011, Vol 128, Num 2, pp 403-411, issn 0091-6749, 9 p.Article

Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosisKING, Talmadge E; SAFRIN, Sharon; STARKO, Karen M et al.Chest. 2005, Vol 127, Num 1, pp 171-177, issn 0012-3692, 7 p.Article

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisRICHELDI, Luca; COSTABEL, Ulrich; BRUN, Michèle et al.The New England journal of medicine. 2011, Vol 365, Num 12, pp 1079-1087, issn 0028-4793, 9 p.Article

CD44 Deficiency Is Associated with Increased Bacterial Clearance but Enhanced Lung Inflammation During Gram-Negative PneumoniaVAN DER WINDT, Gerritje J. W; FLORQUIN, Sandrine; DE VOS, Alex F et al.The American journal of pathology. 2010, Vol 177, Num 5, pp 2483-2494, issn 0002-9440, 12 p.Article

The Role of Surfactant Protein A in Bleomycin-induced Acute Lung InjuryGOTO, Hisatsugu; LEDFORD, Julie G; MUKHERJEE, Sambuddho et al.American journal of respiratory and critical care medicine. 2010, Vol 181, Num 12, pp 1336-1344, issn 1073-449X, 9 p.Article

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialKING, Talmadge E; ALBERA, Carlo; VALEYRE, Dominique et al.Lancet (British edition). 2009, Vol 374, Num 9685, pp 222-228, issn 0140-6736, 7 p.Article

The clinical course of patients with idiopathic pulmonary fibrosisMARTINEZ, Fernando J; SAFRIN, Sharon; BROWN, Kevin K et al.Annals of internal medicine. 2005, Vol 142, Num 12, pp 963-967, issn 0003-4819, 5 p., 1Article

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosisRAGHU, Ganesh; BROWN, Kevin K; BRADFORD, Williamson Z et al.The New England journal of medicine. 2004, Vol 350, Num 2, pp 125-133, issn 0028-4793, 9 p.Article

A macrophage subpopulation recruited by CC chemokine ligand-2 clears apoptotic cells in noninfectious lung injuryJIURONG LIANG; JUNG, Yoosun; TIGHE, Robert M et al.American journal of physiology. Lung cellular and molecular physiology. 2012, Vol 46, Num 5, issn 1040-0605, L933-L940Article

Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III TrialsDU BOIS, Roland M; NATHAN, Steven D; RICHELDI, Luca et al.American journal of respiratory and critical care medicine. 2012, Vol 186, Num 8, pp 712-715, issn 1073-449X, 4 p.Article

Extracorporeal Membrane Oxygenation for Severe Refractory Respiratory Failure Secondary to 2009 H1N1 Influenza ATURNER, David A; REHDER, Kyle J; PETERSON-CARMICHAEL, Stacey L et al.Respiratory care. 2011, Vol 56, Num 7, pp 941-946, issn 0020-1324, 6 p.Article

Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3MARTINU, Tereza; KINNIER, Christine V; PALMER, Scott M et al.The Journal of heart and lung transplantation. 2011, Vol 30, Num 6, pp 717-725, issn 1053-2498, 9 p.Article